KOD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kodiak Sciences Inc (KOD) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite positive analyst ratings and promising drug developments, the recent insider selling, negative price momentum, and financial losses suggest caution. The stock may require further stabilization before being a compelling long-term investment.
The technical indicators show mixed signals. The MACD is positive and contracting, indicating potential bullish momentum. However, the RSI is neutral, and the stock has experienced significant recent price declines (-5.09% in regular trading and -2.60% post-market). Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is currently trading below key resistance levels (R1: 42.3).
Positive Phase 3 results for GLOW2 study in diabetic retinopathy and accelerated Biologics License Application timing for tarcocimab. Analysts have raised price targets significantly, citing strong drug development progress.
Insider selling has surged by 45259.39% in the last month, signaling potential lack of confidence from management. The stock has also experienced significant recent price declines, and options data suggests bearish sentiment.
In Q4 2025, the company reported a net loss of $56.7 million, with EPS at -$1.04 (improved by 23.81% YoY). While cash reserves of $209.9 million are expected to sustain operations into 2027, the company is still facing high R&D expenses ($45.5 million in Q4 2025). Revenue remains at $0, indicating no commercialized products yet.
Analysts are bullish, with multiple firms raising price targets (UBS to $80, H.C. Wainwright to $58, Jefferies to $56). Positive updates on tarcocimab and KSI-501 have driven these upgrades, with expectations of strong long-term potential.
